| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Premenstrual Syndrome | 48 | 2023 | 96 | 9.490 |
Why?
|
| Pregnancy Complications | 33 | 2025 | 391 | 7.380 |
Why?
|
| Substance-Related Disorders | 29 | 2022 | 689 | 6.890 |
Why?
|
| Depressive Disorder, Major | 20 | 2021 | 258 | 4.300 |
Why?
|
| Pregnancy | 68 | 2025 | 2352 | 4.150 |
Why?
|
| Antidepressive Agents | 23 | 2022 | 227 | 3.870 |
Why?
|
| Motivational Interviewing | 10 | 2020 | 42 | 3.630 |
Why?
|
| Anxiety Disorders | 20 | 2022 | 188 | 3.230 |
Why?
|
| Depressive Disorder | 31 | 2017 | 291 | 3.220 |
Why?
|
| Pregnancy Outcome | 12 | 2019 | 188 | 2.780 |
Why?
|
| Premenstrual Dysphoric Disorder | 4 | 2023 | 8 | 2.530 |
Why?
|
| Depression | 18 | 2021 | 857 | 2.530 |
Why?
|
| Female | 164 | 2025 | 30797 | 2.500 |
Why?
|
| Premature Birth | 13 | 2025 | 108 | 2.500 |
Why?
|
| Depression, Postpartum | 11 | 2019 | 162 | 2.240 |
Why?
|
| Mass Screening | 17 | 2022 | 643 | 2.080 |
Why?
|
| Adult | 113 | 2024 | 15728 | 2.080 |
Why?
|
| Referral and Consultation | 11 | 2020 | 408 | 1.940 |
Why?
|
| Prenatal Exposure Delayed Effects | 8 | 2022 | 164 | 1.930 |
Why?
|
| Humans | 175 | 2025 | 59280 | 1.870 |
Why?
|
| Panic Disorder | 14 | 2017 | 30 | 1.850 |
Why?
|
| Psychiatric Status Rating Scales | 38 | 2021 | 384 | 1.840 |
Why?
|
| Mood Disorders | 7 | 2016 | 69 | 1.820 |
Why?
|
| Crisis Intervention | 3 | 2022 | 28 | 1.670 |
Why?
|
| Health Personnel | 7 | 2024 | 340 | 1.640 |
Why?
|
| Pregnant Women | 5 | 2022 | 92 | 1.620 |
Why?
|
| Opioid-Related Disorders | 9 | 2025 | 465 | 1.580 |
Why?
|
| Cigarette Smoking | 5 | 2019 | 52 | 1.570 |
Why?
|
| Stress Disorders, Post-Traumatic | 11 | 2024 | 365 | 1.510 |
Why?
|
| Postpartum Period | 9 | 2024 | 203 | 1.500 |
Why?
|
| Young Adult | 29 | 2024 | 4318 | 1.480 |
Why?
|
| Behavior, Addictive | 3 | 2022 | 75 | 1.450 |
Why?
|
| Surveys and Questionnaires | 16 | 2019 | 2584 | 1.410 |
Why?
|
| Sertraline | 12 | 2023 | 59 | 1.360 |
Why?
|
| Alcoholism | 7 | 2020 | 306 | 1.280 |
Why?
|
| Pregnancy, Unplanned | 5 | 2020 | 22 | 1.270 |
Why?
|
| Alcohol Drinking | 3 | 2022 | 299 | 1.260 |
Why?
|
| Prospective Studies | 33 | 2021 | 3095 | 1.230 |
Why?
|
| Benzodiazepines | 4 | 2019 | 98 | 1.190 |
Why?
|
| Diagnostic and Statistical Manual of Mental Disorders | 7 | 2017 | 123 | 1.180 |
Why?
|
| Fluoxetine | 8 | 2022 | 44 | 1.170 |
Why?
|
| Mental Disorders | 8 | 2021 | 763 | 1.120 |
Why?
|
| Social Support | 6 | 2020 | 357 | 1.100 |
Why?
|
| Paroxetine | 6 | 2013 | 15 | 1.090 |
Why?
|
| Smoking | 6 | 2022 | 830 | 1.060 |
Why?
|
| Connecticut | 12 | 2017 | 86 | 1.040 |
Why?
|
| Menstrual Cycle | 8 | 2022 | 76 | 1.020 |
Why?
|
| Anxiety | 6 | 2022 | 395 | 0.980 |
Why?
|
| Double-Blind Method | 19 | 2023 | 684 | 0.970 |
Why?
|
| Luteal Phase | 15 | 2023 | 27 | 0.970 |
Why?
|
| Women's Health | 7 | 2017 | 390 | 0.960 |
Why?
|
| Antidepressive Agents, Second-Generation | 6 | 2013 | 28 | 0.930 |
Why?
|
| Severity of Illness Index | 27 | 2016 | 1447 | 0.910 |
Why?
|
| Contraceptives, Oral, Hormonal | 3 | 2016 | 18 | 0.880 |
Why?
|
| Mothers | 3 | 2021 | 261 | 0.870 |
Why?
|
| Contraception | 2 | 2021 | 64 | 0.830 |
Why?
|
| Marijuana Use | 2 | 2019 | 15 | 0.810 |
Why?
|
| Intention | 2 | 2022 | 66 | 0.800 |
Why?
|
| Buprenorphine | 2 | 2025 | 186 | 0.800 |
Why?
|
| Reproductive Health Services | 2 | 2019 | 12 | 0.760 |
Why?
|
| Quality of Life | 13 | 2017 | 1108 | 0.750 |
Why?
|
| Adolescent | 26 | 2020 | 5914 | 0.750 |
Why?
|
| Progesterone | 2 | 2017 | 157 | 0.740 |
Why?
|
| Treatment Outcome | 26 | 2023 | 5140 | 0.730 |
Why?
|
| Family Planning Services | 2 | 2022 | 21 | 0.730 |
Why?
|
| Practice Guidelines as Topic | 3 | 2019 | 704 | 0.720 |
Why?
|
| Life Change Events | 5 | 2016 | 66 | 0.710 |
Why?
|
| Motivation | 3 | 2014 | 266 | 0.710 |
Why?
|
| Societies, Medical | 2 | 2019 | 330 | 0.680 |
Why?
|
| Suicide | 2 | 2021 | 123 | 0.670 |
Why?
|
| Recurrence | 12 | 2017 | 576 | 0.670 |
Why?
|
| Abortion, Spontaneous | 1 | 2019 | 29 | 0.670 |
Why?
|
| Interview, Psychological | 4 | 2019 | 76 | 0.660 |
Why?
|
| Androstenes | 3 | 2017 | 3 | 0.660 |
Why?
|
| Prenatal Diagnosis | 1 | 2019 | 39 | 0.650 |
Why?
|
| Self Report | 2 | 2019 | 366 | 0.650 |
Why?
|
| Biological Psychiatry | 1 | 2019 | 1 | 0.650 |
Why?
|
| Infant, Newborn | 11 | 2022 | 1311 | 0.650 |
Why?
|
| Analgesia, Obstetrical | 1 | 2019 | 23 | 0.640 |
Why?
|
| Comorbidity | 20 | 2015 | 1084 | 0.610 |
Why?
|
| Risk Factors | 19 | 2020 | 4997 | 0.610 |
Why?
|
| Stress, Psychological | 3 | 2020 | 443 | 0.610 |
Why?
|
| Infant, Small for Gestational Age | 2 | 2015 | 27 | 0.610 |
Why?
|
| Violence | 3 | 2016 | 149 | 0.590 |
Why?
|
| Middle Aged | 40 | 2020 | 16230 | 0.590 |
Why?
|
| Research Design | 5 | 2024 | 565 | 0.580 |
Why?
|
| Contraception Behavior | 1 | 2017 | 35 | 0.570 |
Why?
|
| Bipolar Disorder | 5 | 2021 | 254 | 0.560 |
Why?
|
| Cost of Illness | 4 | 2017 | 154 | 0.560 |
Why?
|
| Time Factors | 10 | 2017 | 3567 | 0.560 |
Why?
|
| Health Status Indicators | 3 | 2007 | 98 | 0.560 |
Why?
|
| Secondary Prevention | 1 | 2017 | 152 | 0.550 |
Why?
|
| Opiate Substitution Treatment | 1 | 2019 | 192 | 0.550 |
Why?
|
| Biomedical Research | 4 | 2020 | 250 | 0.530 |
Why?
|
| Randomized Controlled Trials as Topic | 9 | 2024 | 666 | 0.530 |
Why?
|
| Analgesics, Opioid | 3 | 2025 | 493 | 0.520 |
Why?
|
| Odds Ratio | 7 | 2016 | 772 | 0.520 |
Why?
|
| Crime Victims | 1 | 2016 | 32 | 0.510 |
Why?
|
| Infant, Premature | 2 | 2015 | 174 | 0.510 |
Why?
|
| Logistic Models | 8 | 2016 | 1252 | 0.510 |
Why?
|
| Body Weight | 2 | 2016 | 378 | 0.510 |
Why?
|
| Phobic Disorders | 6 | 2005 | 15 | 0.510 |
Why?
|
| Contraceptives, Oral | 2 | 2005 | 25 | 0.490 |
Why?
|
| Prenatal Care | 5 | 2022 | 180 | 0.490 |
Why?
|
| Inpatients | 3 | 2020 | 295 | 0.480 |
Why?
|
| Smoking Cessation | 2 | 2017 | 531 | 0.470 |
Why?
|
| Estrogens | 4 | 2005 | 113 | 0.470 |
Why?
|
| Research Personnel | 3 | 2020 | 86 | 0.470 |
Why?
|
| Ethinyl Estradiol | 3 | 2017 | 9 | 0.460 |
Why?
|
| Parenting | 2 | 2012 | 73 | 0.460 |
Why?
|
| Breast Feeding | 3 | 2019 | 138 | 0.450 |
Why?
|
| Counseling | 3 | 2016 | 351 | 0.440 |
Why?
|
| Follow-Up Studies | 14 | 2012 | 2323 | 0.440 |
Why?
|
| Obstetrics | 3 | 2024 | 85 | 0.430 |
Why?
|
| Massachusetts | 8 | 2017 | 2083 | 0.430 |
Why?
|
| Drug Prescriptions | 1 | 2015 | 188 | 0.430 |
Why?
|
| Prevalence | 9 | 2022 | 1279 | 0.420 |
Why?
|
| Gestational Age | 6 | 2017 | 182 | 0.420 |
Why?
|
| Pregnancy Trimesters | 2 | 2011 | 13 | 0.420 |
Why?
|
| Infant Behavior | 1 | 2012 | 4 | 0.420 |
Why?
|
| Anti-Anxiety Agents | 3 | 2004 | 31 | 0.410 |
Why?
|
| Hazardous Substances | 1 | 2012 | 16 | 0.400 |
Why?
|
| United States | 12 | 2021 | 7491 | 0.400 |
Why?
|
| Social Control, Formal | 1 | 2012 | 20 | 0.400 |
Why?
|
| Maternal Health Services | 2 | 2011 | 64 | 0.390 |
Why?
|
| Pain | 1 | 2015 | 406 | 0.390 |
Why?
|
| Gonadotropin-Releasing Hormone | 3 | 2017 | 87 | 0.390 |
Why?
|
| Ambulatory Care Facilities | 3 | 2022 | 102 | 0.380 |
Why?
|
| Electronics | 2 | 2022 | 36 | 0.370 |
Why?
|
| Cohort Studies | 9 | 2013 | 2435 | 0.370 |
Why?
|
| Dietary Supplements | 1 | 2013 | 246 | 0.370 |
Why?
|
| Interviews as Topic | 5 | 2024 | 483 | 0.360 |
Why?
|
| 1-Naphthylamine | 5 | 1997 | 8 | 0.360 |
Why?
|
| Perinatal Care | 1 | 2011 | 61 | 0.350 |
Why?
|
| Child of Impaired Parents | 2 | 2007 | 28 | 0.350 |
Why?
|
| Mother-Child Relations | 1 | 2010 | 46 | 0.350 |
Why?
|
| Reproductive Health | 2 | 2020 | 24 | 0.350 |
Why?
|
| Calcium | 1 | 2013 | 552 | 0.350 |
Why?
|
| Psychology | 2 | 2008 | 47 | 0.350 |
Why?
|
| Combined Modality Therapy | 4 | 2014 | 354 | 0.340 |
Why?
|
| Cost-Benefit Analysis | 5 | 2020 | 287 | 0.340 |
Why?
|
| Urban Population | 3 | 2011 | 182 | 0.340 |
Why?
|
| Nerve Net | 1 | 2010 | 94 | 0.340 |
Why?
|
| Primary Health Care | 3 | 2017 | 645 | 0.340 |
Why?
|
| Antipsychotic Agents | 3 | 2015 | 312 | 0.340 |
Why?
|
| Infant, Low Birth Weight | 3 | 2017 | 58 | 0.320 |
Why?
|
| Physicians | 3 | 2020 | 436 | 0.320 |
Why?
|
| Pilot Projects | 5 | 2020 | 917 | 0.320 |
Why?
|
| Substance Abuse Detection | 2 | 2019 | 39 | 0.320 |
Why?
|
| Research Support as Topic | 2 | 2020 | 44 | 0.320 |
Why?
|
| Diagnosis, Computer-Assisted | 2 | 2019 | 43 | 0.320 |
Why?
|
| Psychometrics | 6 | 2013 | 355 | 0.320 |
Why?
|
| Health Status | 4 | 2017 | 449 | 0.310 |
Why?
|
| Alcohol-Related Disorders | 2 | 2019 | 36 | 0.310 |
Why?
|
| Program Evaluation | 2 | 2020 | 483 | 0.300 |
Why?
|
| Mental Health Services | 2 | 2009 | 298 | 0.300 |
Why?
|
| Male | 39 | 2020 | 27478 | 0.300 |
Why?
|
| Extraembryonic Membranes | 2 | 2025 | 5 | 0.300 |
Why?
|
| Progesterone Congeners | 2 | 2005 | 8 | 0.300 |
Why?
|
| Neonatal Abstinence Syndrome | 2 | 2019 | 33 | 0.290 |
Why?
|
| Faculty, Medical | 2 | 2020 | 202 | 0.290 |
Why?
|
| Sensitivity and Specificity | 3 | 2019 | 1093 | 0.280 |
Why?
|
| Emergency Service, Hospital | 4 | 2024 | 1019 | 0.270 |
Why?
|
| Suicidal Ideation | 2 | 2021 | 113 | 0.270 |
Why?
|
| Anger | 2 | 2016 | 23 | 0.260 |
Why?
|
| Milk, Human | 1 | 2007 | 94 | 0.260 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2008 | 114 | 0.260 |
Why?
|
| Life Style | 1 | 2008 | 328 | 0.260 |
Why?
|
| Contraceptives, Oral, Combined | 1 | 2005 | 5 | 0.260 |
Why?
|
| Women | 2 | 1998 | 46 | 0.250 |
Why?
|
| Drug Administration Schedule | 7 | 2006 | 281 | 0.250 |
Why?
|
| Affect | 2 | 2012 | 121 | 0.250 |
Why?
|
| Health Behavior | 4 | 2015 | 473 | 0.250 |
Why?
|
| Reproducibility of Results | 6 | 2013 | 1546 | 0.250 |
Why?
|
| Cross-Sectional Studies | 7 | 2013 | 2461 | 0.240 |
Why?
|
| Social Adjustment | 4 | 2004 | 34 | 0.230 |
Why?
|
| Child Protective Services | 1 | 2024 | 5 | 0.230 |
Why?
|
| Mandatory Reporting | 1 | 2024 | 18 | 0.230 |
Why?
|
| Public Health Administration | 1 | 2004 | 25 | 0.230 |
Why?
|
| Sex Factors | 9 | 2002 | 959 | 0.230 |
Why?
|
| Poverty | 1 | 2006 | 286 | 0.230 |
Why?
|
| Academic Medical Centers | 2 | 2020 | 314 | 0.220 |
Why?
|
| Regression Analysis | 4 | 2015 | 485 | 0.220 |
Why?
|
| Affective Symptoms | 2 | 2002 | 16 | 0.220 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2024 | 71 | 0.220 |
Why?
|
| Community Health Centers | 1 | 2004 | 92 | 0.210 |
Why?
|
| Financing, Organized | 2 | 2020 | 16 | 0.210 |
Why?
|
| Fetal Membranes, Premature Rupture | 1 | 2022 | 11 | 0.210 |
Why?
|
| Brain | 1 | 2010 | 1487 | 0.200 |
Why?
|
| Restraint, Physical | 1 | 2022 | 31 | 0.200 |
Why?
|
| Personality Inventory | 4 | 2013 | 50 | 0.200 |
Why?
|
| Dysthymic Disorder | 4 | 2013 | 8 | 0.200 |
Why?
|
| Placebos | 8 | 2013 | 72 | 0.190 |
Why?
|
| Hot Flashes | 1 | 2003 | 95 | 0.190 |
Why?
|
| Pregnancy, Unwanted | 2 | 2018 | 10 | 0.190 |
Why?
|
| Reproductive Techniques, Assisted | 1 | 2021 | 31 | 0.190 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2010 | 2034 | 0.190 |
Why?
|
| Sleep, REM | 4 | 2002 | 10 | 0.190 |
Why?
|
| Patient Selection | 1 | 2003 | 445 | 0.190 |
Why?
|
| Prescription Drug Misuse | 2 | 2019 | 22 | 0.190 |
Why?
|
| Socioeconomic Factors | 2 | 2016 | 781 | 0.180 |
Why?
|
| Intimate Partner Violence | 1 | 2021 | 26 | 0.180 |
Why?
|
| Gynecology | 1 | 2021 | 52 | 0.180 |
Why?
|
| Behavioral Symptoms | 1 | 2020 | 15 | 0.180 |
Why?
|
| Occupational Stress | 1 | 2020 | 16 | 0.180 |
Why?
|
| Sex Offenses | 1 | 2021 | 46 | 0.180 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 211 | 0.180 |
Why?
|
| Personnel, Hospital | 1 | 2020 | 39 | 0.180 |
Why?
|
| Transsexualism | 1 | 2020 | 13 | 0.170 |
Why?
|
| Irritable Mood | 3 | 2015 | 15 | 0.170 |
Why?
|
| Health Plan Implementation | 1 | 2020 | 42 | 0.170 |
Why?
|
| Linear Models | 2 | 2013 | 419 | 0.170 |
Why?
|
| Resilience, Psychological | 1 | 2020 | 50 | 0.170 |
Why?
|
| Self-Assessment | 3 | 2008 | 54 | 0.170 |
Why?
|
| Patient Participation | 1 | 2022 | 209 | 0.170 |
Why?
|
| Mindfulness | 1 | 2020 | 64 | 0.170 |
Why?
|
| Gender Identity | 1 | 2020 | 61 | 0.170 |
Why?
|
| Feeding and Eating Disorders | 1 | 2020 | 47 | 0.170 |
Why?
|
| Smoking Reduction | 1 | 2019 | 2 | 0.170 |
Why?
|
| Follicular Phase | 6 | 2005 | 14 | 0.160 |
Why?
|
| Patient Acceptance of Health Care | 1 | 2003 | 446 | 0.160 |
Why?
|
| Transgender Persons | 1 | 2020 | 62 | 0.160 |
Why?
|
| Therapy, Computer-Assisted | 1 | 2019 | 24 | 0.160 |
Why?
|
| Psychotherapy | 4 | 2011 | 89 | 0.160 |
Why?
|
| Adaptation, Psychological | 2 | 2004 | 263 | 0.160 |
Why?
|
| Patient Satisfaction | 2 | 2019 | 413 | 0.160 |
Why?
|
| Clinical Trials as Topic | 3 | 2002 | 439 | 0.160 |
Why?
|
| Ovariectomy | 2 | 2017 | 97 | 0.160 |
Why?
|
| Prognosis | 3 | 2011 | 1564 | 0.160 |
Why?
|
| Education | 1 | 2019 | 74 | 0.160 |
Why?
|
| Program Development | 1 | 2019 | 210 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 159 | 0.150 |
Why?
|
| Foundations | 1 | 2018 | 8 | 0.150 |
Why?
|
| Tobacco Use Disorder | 2 | 2017 | 245 | 0.150 |
Why?
|
| Binge Drinking | 1 | 2018 | 29 | 0.150 |
Why?
|
| Delivery of Health Care | 2 | 2019 | 421 | 0.150 |
Why?
|
| Sexism | 1 | 2018 | 31 | 0.150 |
Why?
|
| Cocaine-Related Disorders | 1 | 2018 | 75 | 0.150 |
Why?
|
| Longitudinal Studies | 9 | 2005 | 1224 | 0.150 |
Why?
|
| Qualitative Research | 4 | 2024 | 605 | 0.150 |
Why?
|
| Tobacco Smoking | 1 | 2017 | 19 | 0.150 |
Why?
|
| Fatty Acids, Unsaturated | 1 | 2017 | 33 | 0.150 |
Why?
|
| Harm Reduction | 1 | 2017 | 24 | 0.150 |
Why?
|
| Caregivers | 1 | 2020 | 216 | 0.150 |
Why?
|
| Education, Medical | 1 | 2019 | 175 | 0.140 |
Why?
|
| Salpingectomy | 1 | 2017 | 5 | 0.140 |
Why?
|
| Craving | 1 | 2017 | 35 | 0.140 |
Why?
|
| Public Health Practice | 1 | 2017 | 18 | 0.140 |
Why?
|
| Pain Management | 1 | 2019 | 143 | 0.140 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 186 | 0.140 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 198 | 0.140 |
Why?
|
| Risk Assessment | 3 | 2014 | 1907 | 0.140 |
Why?
|
| Hypertension, Pregnancy-Induced | 1 | 2017 | 51 | 0.140 |
Why?
|
| Hysterectomy | 1 | 2017 | 70 | 0.140 |
Why?
|
| California | 2 | 2007 | 160 | 0.140 |
Why?
|
| Medical Records | 3 | 2007 | 137 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2017 | 60 | 0.140 |
Why?
|
| Psychotropic Drugs | 3 | 1997 | 83 | 0.130 |
Why?
|
| Cesarean Section | 1 | 2017 | 96 | 0.130 |
Why?
|
| Smoking Prevention | 1 | 2017 | 162 | 0.130 |
Why?
|
| Mobile Applications | 1 | 2017 | 130 | 0.130 |
Why?
|
| Education, Continuing | 1 | 2015 | 24 | 0.130 |
Why?
|
| Hospitals, University | 1 | 2015 | 50 | 0.130 |
Why?
|
| Cross-Over Studies | 2 | 2006 | 148 | 0.130 |
Why?
|
| Prenatal Injuries | 1 | 2015 | 1 | 0.130 |
Why?
|
| Physician Assistants | 1 | 2015 | 37 | 0.130 |
Why?
|
| Pregnancy, High-Risk | 2 | 2015 | 22 | 0.120 |
Why?
|
| Pandemics | 1 | 2020 | 606 | 0.120 |
Why?
|
| Women's Health Services | 2 | 2006 | 31 | 0.120 |
Why?
|
| Inservice Training | 1 | 2015 | 83 | 0.120 |
Why?
|
| Absenteeism | 2 | 2006 | 38 | 0.120 |
Why?
|
| Child, Preschool | 2 | 2016 | 1837 | 0.120 |
Why?
|
| Analysis of Variance | 3 | 2009 | 576 | 0.120 |
Why?
|
| Birth Weight | 2 | 2015 | 83 | 0.120 |
Why?
|
| Respiration, Artificial | 1 | 2017 | 285 | 0.120 |
Why?
|
| Electroencephalography | 2 | 1998 | 136 | 0.120 |
Why?
|
| Nurses | 1 | 2015 | 103 | 0.120 |
Why?
|
| Sleep | 2 | 2012 | 218 | 0.120 |
Why?
|
| Fetal Development | 2 | 2015 | 17 | 0.110 |
Why?
|
| Infant | 2 | 2010 | 1527 | 0.110 |
Why?
|
| Persistent Fetal Circulation Syndrome | 1 | 2013 | 4 | 0.110 |
Why?
|
| Dose-Response Relationship, Drug | 5 | 2005 | 810 | 0.110 |
Why?
|
| Reaction Time | 1 | 1994 | 119 | 0.110 |
Why?
|
| Psychopharmacology | 1 | 1993 | 13 | 0.110 |
Why?
|
| Telemedicine | 1 | 2019 | 333 | 0.110 |
Why?
|
| Rhode Island | 1 | 2013 | 97 | 0.110 |
Why?
|
| Triazoles | 3 | 1998 | 55 | 0.110 |
Why?
|
| Multivariate Analysis | 1 | 2015 | 926 | 0.110 |
Why?
|
| Disease Progression | 3 | 2003 | 1039 | 0.110 |
Why?
|
| Emotions | 2 | 2017 | 217 | 0.100 |
Why?
|
| Incidence | 3 | 2011 | 1232 | 0.100 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2012 | 25 | 0.100 |
Why?
|
| Heart Defects, Congenital | 1 | 2013 | 95 | 0.100 |
Why?
|
| Agoraphobia | 4 | 1998 | 10 | 0.100 |
Why?
|
| Personality Assessment | 2 | 2007 | 21 | 0.100 |
Why?
|
| Interleukin-6 | 2 | 2025 | 309 | 0.100 |
Why?
|
| Hospitalization | 1 | 2019 | 1278 | 0.100 |
Why?
|
| Menstruation | 1 | 2012 | 31 | 0.100 |
Why?
|
| Infant, Newborn, Diseases | 1 | 2012 | 33 | 0.100 |
Why?
|
| Consensus | 1 | 2013 | 193 | 0.100 |
Why?
|
| Parturition | 1 | 2012 | 53 | 0.100 |
Why?
|
| Remission Induction | 2 | 2003 | 137 | 0.100 |
Why?
|
| Attention | 2 | 2010 | 153 | 0.100 |
Why?
|
| Residential Treatment | 1 | 2012 | 34 | 0.100 |
Why?
|
| Child Development | 1 | 2012 | 79 | 0.100 |
Why?
|
| Psychotic Disorders | 1 | 1993 | 150 | 0.100 |
Why?
|
| Diagnosis, Differential | 4 | 2013 | 895 | 0.090 |
Why?
|
| Healthy People Programs | 1 | 2011 | 12 | 0.090 |
Why?
|
| ROC Curve | 2 | 2009 | 259 | 0.090 |
Why?
|
| Predictive Value of Tests | 3 | 2009 | 1024 | 0.090 |
Why?
|
| Imipramine | 3 | 2000 | 3 | 0.090 |
Why?
|
| Efficiency | 2 | 2003 | 41 | 0.090 |
Why?
|
| Maternal Behavior | 1 | 2010 | 31 | 0.090 |
Why?
|
| Amygdala | 1 | 2010 | 78 | 0.090 |
Why?
|
| Age of Onset | 4 | 1998 | 173 | 0.090 |
Why?
|
| Statistics, Nonparametric | 1 | 2010 | 208 | 0.090 |
Why?
|
| Child | 4 | 2021 | 4298 | 0.090 |
Why?
|
| Prefrontal Cortex | 1 | 2010 | 112 | 0.090 |
Why?
|
| Proportional Hazards Models | 1 | 2011 | 672 | 0.090 |
Why?
|
| Exercise | 1 | 2017 | 913 | 0.080 |
Why?
|
| Attitude to Health | 1 | 2012 | 275 | 0.080 |
Why?
|
| Cyclohexanols | 2 | 2001 | 17 | 0.080 |
Why?
|
| Motor Activity | 1 | 2012 | 342 | 0.080 |
Why?
|
| Lithium Carbonate | 2 | 2004 | 11 | 0.080 |
Why?
|
| Chronic Disease | 6 | 2005 | 731 | 0.080 |
Why?
|
| Single-Blind Method | 3 | 2005 | 134 | 0.080 |
Why?
|
| Remission, Spontaneous | 2 | 2000 | 14 | 0.080 |
Why?
|
| Health Care Reform | 1 | 2009 | 88 | 0.080 |
Why?
|
| Aged | 12 | 2013 | 13285 | 0.080 |
Why?
|
| Psychophysiology | 1 | 2008 | 6 | 0.080 |
Why?
|
| Personality | 1 | 2007 | 25 | 0.070 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2007 | 32 | 0.070 |
Why?
|
| Demography | 1 | 2008 | 178 | 0.070 |
Why?
|
| Models, Psychological | 1 | 2008 | 92 | 0.070 |
Why?
|
| Interpersonal Relations | 1 | 2008 | 150 | 0.070 |
Why?
|
| Case Management | 1 | 2008 | 61 | 0.070 |
Why?
|
| Probability | 4 | 2005 | 172 | 0.070 |
Why?
|
| Data Collection | 2 | 2006 | 384 | 0.070 |
Why?
|
| Models, Organizational | 1 | 2008 | 92 | 0.070 |
Why?
|
| Inflammation | 2 | 2025 | 1100 | 0.070 |
Why?
|
| Psychomotor Agitation | 2 | 2022 | 19 | 0.070 |
Why?
|
| Delphi Technique | 1 | 2007 | 83 | 0.070 |
Why?
|
| Drug Therapy, Combination | 2 | 2006 | 434 | 0.070 |
Why?
|
| Health Surveys | 1 | 2007 | 306 | 0.070 |
Why?
|
| Diagnosis, Dual (Psychiatry) | 1 | 2006 | 78 | 0.070 |
Why?
|
| Memory Disorders | 1 | 2006 | 44 | 0.070 |
Why?
|
| gamma-Aminobutyric Acid | 2 | 1997 | 79 | 0.060 |
Why?
|
| Somatoform Disorders | 3 | 2009 | 13 | 0.060 |
Why?
|
| Activities of Daily Living | 2 | 2013 | 298 | 0.060 |
Why?
|
| Mental Recall | 1 | 2006 | 94 | 0.060 |
Why?
|
| Uterine Hemorrhage | 1 | 2005 | 20 | 0.060 |
Why?
|
| Serotonin | 1 | 2006 | 66 | 0.060 |
Why?
|
| Patient Compliance | 2 | 2006 | 371 | 0.060 |
Why?
|
| Dinoprostone | 1 | 2025 | 45 | 0.060 |
Why?
|
| Patient Care Team | 2 | 2020 | 324 | 0.060 |
Why?
|
| Carbamazepine | 1 | 2004 | 11 | 0.060 |
Why?
|
| Fetal Diseases | 1 | 2004 | 21 | 0.060 |
Why?
|
| Triazines | 1 | 2004 | 20 | 0.060 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 47 | 0.060 |
Why?
|
| Valproic Acid | 1 | 2004 | 25 | 0.060 |
Why?
|
| Antimanic Agents | 1 | 2004 | 29 | 0.060 |
Why?
|
| Health Services Accessibility | 1 | 2009 | 542 | 0.060 |
Why?
|
| Health Care Costs | 2 | 2017 | 200 | 0.060 |
Why?
|
| Algorithms | 1 | 2009 | 986 | 0.060 |
Why?
|
| Substance Withdrawal Syndrome | 1 | 2005 | 117 | 0.060 |
Why?
|
| Anticonvulsants | 1 | 2004 | 94 | 0.050 |
Why?
|
| Interleukin-1beta | 1 | 2025 | 263 | 0.050 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2025 | 347 | 0.050 |
Why?
|
| Drug Tolerance | 1 | 2003 | 28 | 0.050 |
Why?
|
| Informed Consent | 1 | 2024 | 133 | 0.050 |
Why?
|
| Reference Values | 3 | 2002 | 323 | 0.050 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2025 | 256 | 0.050 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2002 | 25 | 0.050 |
Why?
|
| Pharmacogenetics | 1 | 2002 | 22 | 0.050 |
Why?
|
| Piperazines | 3 | 1998 | 96 | 0.050 |
Why?
|
| Observer Variation | 1 | 2003 | 201 | 0.050 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2022 | 125 | 0.050 |
Why?
|
| Sex Distribution | 1 | 2003 | 254 | 0.050 |
Why?
|
| Drug Interactions | 1 | 2002 | 115 | 0.050 |
Why?
|
| Aggression | 1 | 2022 | 57 | 0.050 |
Why?
|
| Patient Outcome Assessment | 1 | 2022 | 55 | 0.050 |
Why?
|
| Ambulatory Care | 3 | 2000 | 299 | 0.050 |
Why?
|
| Polymorphism, Genetic | 1 | 2002 | 197 | 0.050 |
Why?
|
| Venlafaxine Hydrochloride | 2 | 2001 | 15 | 0.050 |
Why?
|
| Inflammasomes | 1 | 2025 | 324 | 0.050 |
Why?
|
| Acute Disease | 2 | 1993 | 658 | 0.050 |
Why?
|
| Forecasting | 1 | 2001 | 221 | 0.050 |
Why?
|
| Physician-Patient Relations | 1 | 2024 | 386 | 0.050 |
Why?
|
| Antidepressive Agents, Tricyclic | 1 | 2000 | 20 | 0.050 |
Why?
|
| Survival Analysis | 3 | 2013 | 553 | 0.040 |
Why?
|
| Evaluation Studies as Topic | 1 | 2020 | 104 | 0.040 |
Why?
|
| Cells, Cultured | 1 | 2025 | 2102 | 0.040 |
Why?
|
| Longevity | 1 | 2021 | 111 | 0.040 |
Why?
|
| Menopause | 1 | 2003 | 246 | 0.040 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 558 | 0.040 |
Why?
|
| Focus Groups | 1 | 2021 | 290 | 0.040 |
Why?
|
| Social Stigma | 1 | 2020 | 67 | 0.040 |
Why?
|
| Alprazolam | 1 | 1999 | 4 | 0.040 |
Why?
|
| Polysomnography | 2 | 2002 | 54 | 0.040 |
Why?
|
| GTP-Binding Protein alpha Subunits, Gi-Go | 1 | 1998 | 15 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha-2 | 1 | 1998 | 19 | 0.040 |
Why?
|
| Sexual and Gender Minorities | 1 | 2020 | 73 | 0.040 |
Why?
|
| Receptors, Adrenergic, beta-2 | 1 | 1998 | 10 | 0.040 |
Why?
|
| Chi-Square Distribution | 1 | 1999 | 403 | 0.040 |
Why?
|
| Career Choice | 1 | 2019 | 110 | 0.040 |
Why?
|
| Family | 2 | 1997 | 219 | 0.040 |
Why?
|
| Wakefulness | 2 | 1998 | 38 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2020 | 522 | 0.040 |
Why?
|
| GTP-Binding Proteins | 1 | 1998 | 80 | 0.040 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 1 | 1998 | 47 | 0.040 |
Why?
|
| Sleep Stages | 1 | 1997 | 16 | 0.040 |
Why?
|
| Legislation as Topic | 1 | 2017 | 11 | 0.040 |
Why?
|
| Happiness | 1 | 2017 | 9 | 0.040 |
Why?
|
| Clomipramine | 1 | 1997 | 1 | 0.040 |
Why?
|
| Sodium Lactate | 1 | 1997 | 1 | 0.040 |
Why?
|
| Buspirone | 1 | 1997 | 3 | 0.040 |
Why?
|
| Endorphins | 1 | 1997 | 12 | 0.040 |
Why?
|
| Lithium | 1 | 1997 | 13 | 0.030 |
Why?
|
| Carbon Dioxide | 1 | 1997 | 75 | 0.030 |
Why?
|
| Blood Platelets | 1 | 1998 | 178 | 0.030 |
Why?
|
| Postnatal Care | 1 | 2016 | 41 | 0.030 |
Why?
|
| Hospitals, Teaching | 1 | 1996 | 102 | 0.030 |
Why?
|
| Terminology as Topic | 1 | 1997 | 138 | 0.030 |
Why?
|
| Abnormalities, Drug-Induced | 1 | 2015 | 21 | 0.030 |
Why?
|
| Drug Users | 1 | 2014 | 27 | 0.030 |
Why?
|
| Dissociative Disorders | 1 | 1993 | 7 | 0.030 |
Why?
|
| Georgia | 1 | 2014 | 88 | 0.030 |
Why?
|
| Mental Health | 1 | 2017 | 348 | 0.030 |
Why?
|
| Signal Processing, Computer-Assisted | 1 | 1994 | 98 | 0.030 |
Why?
|
| Personality Development | 1 | 1993 | 6 | 0.030 |
Why?
|
| Mathematical Computing | 1 | 1993 | 12 | 0.030 |
Why?
|
| Group Processes | 1 | 2013 | 41 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 371 | 0.030 |
Why?
|
| Cerebral Cortex | 1 | 1994 | 253 | 0.030 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 739 | 0.020 |
Why?
|
| Biomarkers | 1 | 1997 | 1205 | 0.020 |
Why?
|
| Wounds and Injuries | 1 | 1993 | 234 | 0.020 |
Why?
|
| Insurance Carriers | 1 | 2009 | 4 | 0.020 |
Why?
|
| Financing, Government | 1 | 2009 | 33 | 0.020 |
Why?
|
| Politics | 1 | 2009 | 31 | 0.020 |
Why?
|
| Government Regulation | 1 | 2009 | 44 | 0.020 |
Why?
|
| Social Behavior | 1 | 2009 | 88 | 0.020 |
Why?
|
| Factor Analysis, Statistical | 1 | 2008 | 104 | 0.020 |
Why?
|
| Estrogen Antagonists | 1 | 2006 | 17 | 0.020 |
Why?
|
| Cognition Disorders | 1 | 2008 | 217 | 0.020 |
Why?
|
| MEDLINE | 1 | 2006 | 19 | 0.020 |
Why?
|
| Meta-Analysis as Topic | 1 | 2006 | 77 | 0.020 |
Why?
|
| Individuality | 1 | 2005 | 21 | 0.020 |
Why?
|
| Decision Making | 1 | 2008 | 387 | 0.010 |
Why?
|
| Confidence Intervals | 1 | 2004 | 256 | 0.010 |
Why?
|
| Delayed-Action Preparations | 1 | 2004 | 105 | 0.010 |
Why?
|
| Central Nervous System | 1 | 2006 | 191 | 0.010 |
Why?
|
| Sleep Wake Disorders | 1 | 2002 | 68 | 0.010 |
Why?
|
| Patient Dropouts | 1 | 2000 | 48 | 0.010 |
Why?
|
| Premenopause | 1 | 2000 | 57 | 0.010 |
Why?
|
| Iodocyanopindolol | 1 | 1998 | 1 | 0.010 |
Why?
|
| Pindolol | 1 | 1998 | 2 | 0.010 |
Why?
|
| Receptors, Serotonin | 1 | 1998 | 17 | 0.010 |
Why?
|
| Radioligand Assay | 1 | 1998 | 24 | 0.010 |
Why?
|
| Iodine Radioisotopes | 1 | 1998 | 51 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2002 | 677 | 0.010 |
Why?
|
| Personality Disorders | 1 | 1997 | 18 | 0.010 |
Why?
|
| Up-Regulation | 1 | 1998 | 363 | 0.010 |
Why?
|
| Outpatients | 1 | 1997 | 131 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 1998 | 1058 | 0.010 |
Why?
|
| Circadian Rhythm | 1 | 1998 | 370 | 0.010 |
Why?
|
| Age Factors | 1 | 1998 | 1518 | 0.010 |
Why?
|
| Stomach Ulcer | 1 | 1994 | 7 | 0.010 |
Why?
|
| Angina Pectoris | 1 | 1994 | 36 | 0.010 |
Why?
|
| Child Abuse, Sexual | 1 | 1993 | 21 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 1994 | 26 | 0.010 |
Why?
|
| Protein Binding | 1 | 1998 | 1545 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 1995 | 199 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1994 | 5063 | 0.000 |
Why?
|